MON-LB101 Pharmacokinetics of Liothyronine during Thyroid Hormone Therapy Withdrawal

Background Liothyronine (LT3) is a substitute for levothyroxine (LT4) for thyroid cancer patients during the preparation for nuclear medicine procedures, and there is renewed interest in its use in combination with LT4 in patients who do not respond to the standard treatment. This therapy is commonl...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Endocr Soc
Prif Awduron: Celi, Francesco, Wohlford, George, Linderman, Joyce, Smith, Sheila, Yavuz, Sahzene, Pucino, Frank, Van Tassell, Benjamin
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Endocrine Society 2019
Pynciau:
Thyroid
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6550962/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-MON-LB101
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg